Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector
By Xcenda
We take a look at the mergers and acquisition activity in the life science sector as result of the Tax Cuts and Jobs Act (TCJA) and provides key insights for investing in the sector.
ISSUE BRIEF
Life Science Investing During the US Tax Reform Windfall: Key Insights to Guide Smart Decision Making
On December 22, 2017, President Donald Trump signed into law the Tax Cuts and Jobs Act (TCJA), which has since been described as a windfall for corporate tax infrastructure and the most far-reaching piece of tax legislation enacted in the United States (US) since the Tax Reform Act of 1986.1 The TCJA has been of keen interest among the life science investment community before and after it was signed into law due to the potential for US companies to repatriate their liquid foreign subsidiaries at a lower tax rate.
In this issue brief, we examine:
- Current life science investment activity since TCJA
- Key considerations for asset evaluation
- What to look for in a due diligence partner to guide mergers and acquisition activity in the life science sector
Topics:
Legislation
.jpg?h=320&iar=0&w=540&useCustomFunctions=1¢erCrop=1&hash=D3212DEB9EF225EFD30381936A4BEC29)